F&G at KBW Insurance Conference 2026: fee shift, growth push

F&G outlined a capital-light growth strategy targeting gross AUM growth of about 8% annually ($6B), retained AUM growth of $2B-$3B per year, and fee-based earnings of 25% by 2028 versus 15% at year-end 2025. Management targets ROE expansion to 14% from roughly 11%-12%, supported by reinsurance, while its expense ratio has fallen to 47bps and is expected to reach 45bps by year-end 2026. The company is reviewing strategic alternatives for Peak Altitude, which produces $80M-$85M of EBITDA and represents 30% of life sales, while emphasizing that its shares trade near half of book value despite approximately $1B in annual organic capital generation. Key offsets include elevated surrenders, slower IUL affordability-driven volumes, subdued first-half PRT activity, and alternative-investment returns of about 7% versus a 12% long-term target.

Analysis

FG’s rerating case depends less on headline AUM growth than on proving that capital-light growth converts into durable per-share value. Reinsurance can lift reported ROE by reducing required capital, but it also shifts economics and asset upside to counterparties; the market will demand evidence that ceding commissions, rather than reserve releases or favorable investment marks, are driving the improvement. The key 1-3 month catalyst is a Peak Altitude transaction with a transparent cash valuation and explicit capital allocation, which could force a more credible sum-of-the-parts framework.

The near-term macro setup is mixed. Higher-for-longer rates support reinvestment yields and the economics of annually repriced fixed-indexed products, but simultaneously extend surrender pressure and constrain affordability-sensitive life sales. That makes FG more exposed to retail cash-flow behavior than MET, while BHF is a cleaner liquid-public-markets/annuity beta; a sharp rate decline would reduce surrender pressure but could compress new-money spreads and weaken the current annuity demand backdrop.

Peak is strategically double-edged: monetization could crystallize value and reduce holding-company leverage, but a sale to a third-party distributor risks weakening a differentiated origination channel and raising distribution compensation over time. The more consequential 6-18 month risk is that the private-equity alternative portfolio fails to realize near management’s modeled return normalization; this would directly constrain excess capital and undermine both buybacks and the intended ROE expansion. Management’s value claims should therefore be treated as a thesis to validate through statutory capital generation, realized alternative gains, and book-value-per-share growth—not as a standalone catalyst.

Contrarian view: the discount may reflect structural skepticism rather than simple neglect. Investors may be correctly assigning a lower multiple to an insurer whose earnings mix increasingly relies on reinsurance capacity, affiliated asset-management ecosystems, and a still-unproven distribution monetization. Upside is meaningful if Peak is monetized without sales leakage and capital returns accelerate; downside is asymmetric if reinsurance pricing tightens while surrender rates remain elevated, because the same model that improves capital efficiency can amplify dependence on external partners.

Key Decisions for Investors

• Initiate a 6-12 month long FG / short BHF pair only if FG remains at a material discount to reported book value after adjusting for alternative-asset marks. Thesis: Peak monetization plus buybacks can narrow the valuation gap, while BHF provides a hedge against broad annuity-sector and rate sensitivity. Exit if FG’s next two quarters fail to show ROE progression toward 12%+ or if surrender-related pressure causes a material cut to capital-generation expectations.
• Treat a Peak transaction as the actionable event trigger rather than buying solely on conference commentary. Add to FG if the deal implies a valuation materially above carrying value, preserves meaningful economics/board influence, and commits proceeds to debt reduction or repurchases; avoid if a full sale materially reduces proprietary life-sales access or replaces recurring fee income with a one-time gain.
• Monitor BX as a second-order beneficiary, not a standalone event trade. Incremental reinsurance and retained-asset management can deepen fee-related asset-management economics, but the financial impact is likely immaterial relative to BX’s scale; a meaningful signal would be disclosed growth in insurance AUM or new sidecar commitments.
• Set a downside alert on FG around a deterioration in fixed-income credit losses, alternative-investment realizations, or reinsurance counterparties’ willingness to quote flow business. Any of these would challenge the capital-light narrative and likely justify multiple compression before reported earnings fully reflect the damage.